DNAP is on the right track. On their own or in collaberation with Big Pharm. Going long on this long shot. The following article dhows a vote of confidence in genetic drug research. Com'on DNAP!
Perlegen in 4-Year Pfizer Collaboration AP MOUNTAIN VIEW, Calif. (AP) - Perlegen Sciences Inc., a biotech spin-off of genetics researcher Affymetrix Inc., said Wednesday it is working with drug maker Pfizer Inc. on a four-year research collaboration.
Shares of Affymetrix jumped on the news, adding $3.29, or 7.5 percent, to $47 in morning trading on the Nasdaq. Over the past year, the stock has traded in a range of $33.94 to $59.73.
The project centers on whole genome and replication studies designed to identify genes associated with certain major diseases and patient responses to certain medicines.
Pfizer and Perlegen scientists began their first collaboration in December 2002, conducting genetic research on thousands of DNA samples in areas such as metabolic syndrome and drug response in patients with Major Depression Disorder.
Under the terms of the agreement, Perlegen and Pfizer will share in certain intellectual property rights and Pfizer will pay Perlegen for research.
Researchers from both companies will conduct whole genome studies involving DNA samples from clinical trials with scientists designing the research and analyzing the results.
Shares of Pfizer rose 8 cents to $23.71 in morning trading on the New York Stock Exchange.
Posted by DWE on :
Why are you using the old ticker symbol?
Posted by AtHomeDad on :
WHY? Tell me why I'll keep writing 2005 until July 2006. On second thought, don't answer that.
Ok Ok Ok....DNAG
Posted by OO7 on :
looks like a momo run this morning, if this thing break .035 its off to the races!!
Posted by Squire38 on :